GSK Begins Domestic Administration of World’s First RSV Vaccine Arexvy

Available for Vaccination at Hospitals and Clinics Nationwide Starting Early June

Korea GSK announced on May 29 that it has begun administering its respiratory syncytial virus (RSV) vaccine, Arexvy, in Korea. As a result, Arexvy vaccinations are expected to become available at hospitals and clinics nationwide starting in early June.

Reference image. Korea GSK

Arexvy, the world’s first RSV vaccine, received approval from the Ministry of Food and Drug Safety in December 2024 for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older. RSV infections can occur at any time throughout the year, and adults aged 60 and older, as well as those with underlying conditions such as heart or lung disease, are at risk of developing severe complications like pneumonia if infected with RSV. In severe cases, this can lead to hospitalization or death, making vaccination an important preventive measure.

Arexvy is administered as a single 0.5 mL intramuscular injection. Clinical studies showed that a single dose provided an 82.6% efficacy in preventing RSV-LRTD during the first RSV season among adults aged 60 and older, and a 94.6% efficacy among adults aged 60 and older with at least one underlying medical condition. In addition, Arexvy has been shown to maintain a significant preventive effect over three RSV seasons with just one dose.

This content was produced with the assistance of AI translation services.